Potential in Neurological Disorders Research

Preclinical and some clinical studies suggest GLP-1 RAs have neuroprotective effects, showing potential in treating neurodegenerative diseases like Parkinson's and Alzheimer's, and conditions like idiopathic intracranial hypertension.

Sources

• GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools? - PMC
• Neurodegenerative Disorders and Other Emerging Areas - Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders - NCBI
• Glucagon-like peptide-1 medicines in neurological and psychiatric disorders - PMC
• Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
• GLP-1 receptor agonists in neurological diseases: mechanisms and therapeutic prospects from metabolism to neuroprotection - Frontiers
• The Neurologic Effects of Those Popular Weight Loss Drugs Come Into Focus

Open the full topic